Introduction
- Despite the presence of well tried and liked compounds for the treatment
of diabetes, such as insulin, metformin and sulfonylureas and the recent
introduction of new classes such as TZDs, AGIs and PGRs, there are still
important unmet needs in the treatment of diabetes. As a result, a great
surge of activity towards the discovery and development of new agents has
been recently noted.
Scope of this report
- Evaluation of patient potential for developmental antidiabetics over the
period 2004-2012
- Scrutiny of key impacts on the R&D approach and cost, evaluation of
optimal clinical trial end points and identification of suitable
comparators.
- Evaluation of key players in the antidiabetics market and opposing company
approaches to development and commercialization
- Analysis of key antidiabetic drugs in development and their ability to
satisfy major unmet needs and compete with existing agents
Research and analysis highlights
- One of the most exciting classes of agents in development is GLP-1
agonists. There have been suggestions that these agents will exhibit
efficacy over an extended period of time and that they will offer some
effect on beta-cell preservation. However, these findings need to be
conclusively proven through specifically designed trials.
- DPPIV inhibitors are expected to enter the market in the following years.
Their main advantage is their mode of administration. They will be available
as pills or capsules, contrary to GLP-1 agonists that will be injectable.
This makes them far more attractive and is likely to help their faster
uptake and increased patient compliance.
- Dual PPAR agonists were once hailed as the next big development in the
diabetes treatment. However the recent withdrawal of many leading agents
following safety concerns has prompted the FDA to request additional safety
data before considering the approval of such compounds. This development
will severely delay the progress of dual PPAR analogs.
Key reasons to read this report
- View independent forecasts of sales in late stage development for
treatment of diabetes in novel classes
- Understand physicians views on incretin mimetics as the potential next
big development in the diabetes treatment
- Identify early stage antidiabetic compounds with high potential being
developed by companies seeking a marketing partner
View Cart
